Keywords: oxford, biomedica, loss, increases, uk-based, gene, therapy

Oxford BioMedica's loss increases 7%

Article | 17 September 2007

Print This

UK-based gene therapy developer Oxford BioMedica posted a L9.3 million ($18.9 million) loss for the six months ended June 30, up 6.9% on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in